Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer

Cancer

Volumn 121, Issue 9, 2015, Pages 1395-1404

  Moreira, Leticia ^a   Muñoz, Jenifer ^a   Cuatrecasas, Míriam ^b   Quintanilla, Isabel ^a   Leoz, Maria Liz ^a   Carballal, Sabela ^a   Ocaña, Teresa ^a   Lõpez Cerõn, María ^a   Pellise, Maria ^a   Castellví Bel, Sergi ^a   Jover, Rodrigo ^c   Andreu, Montserrat ^d   Carracedo, Angel ^e   Xicola, Rosa Maria ^f   Llor, Xavier ^f   Boland, Clement Richard ^g   Goel, Ajay ^g   Castells, Antoni ^a   Balaguer, Francesc ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

colorectal cancer; CpG island methylator phenotype; Lynch syndrome; methylation; microsatellite instability; mutL homolog 1; v Raf murine sarcoma viral oncogene homolog B1

Indexed keywords

B RAF KINASE; PROTEIN MLH1; BRAF PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FAMILY HISTORY; FEMALE; GENE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; MUTL HOMOLOG 1 GENE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PYROSEQUENCING; SOMATIC MUTATION; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETICS; MIDDLE AGED; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NUCLEAR PROTEINS; PREVALENCE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84928225617     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29190     Document Type: Article

References (26)

1. Vasen HF, Boland CR,. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA. 2005; 293: 2028-2030.
2. Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet. 2006; 14: 390-402.
3. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M,. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363: 558-561.
4. Cicek MS, Lindor NM, Gallinger S, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011; 13: 271-281.
5. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006; 130: 665-671.
6. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013; 62: 812-823.
7. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58: 3455-3460.
8. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013; 144: 926-932, e921; quiz e913-e924.
9. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014; 146: 643-646, e648.
10. Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013; 463: 613-621.
11. Kaz A, Kim YH, Dzieciatkowski S, et al. Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. Int J Cancer. 2007; 120: 1922-1929.
12. Perez-Carbonell L, Alenda C, Paya A, et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 2010; 12: 498-504.
13. Deng G, Chen A, Hong J, Chae HS, Kim YS,. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999; 59: 2029-2033.
14. Lof-Ohlin ZM, Nilsson TK,. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. Oncol Rep. 2009; 21: 721-729.
15. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012; 61: 865-872.
16. Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010; 70: 6609-6618.
17. Suter CM, Martin DI, Ward RL,. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004; 36: 497-501.
18. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012; 308: 1555-1565.
19. Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2008; 6: 206-214.
20. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A,. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010; 7: 197-208.
21. Ang PW, Loh M, Liem N, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features [serial online]. BMC Cancer. 2010; 10: 227.
22. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB,. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012; 49: 151-157.
23. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 2007; 13: 3221-3228.
24. Gausachs M, Mur P, Corral J, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet. 2012; 20: 762-768.
25. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P,. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol. 2000; 156: 1773-1779.
26. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007; 356: 697-705.